Company news
Rocket Pharmaceuticals, Inc. news in 2020
Rocket Pharmaceuticals, Inc.'s news releases, calls and decks from 2020, newest first.
Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
December 13, 2020
Rocket Pharmaceuticals Prices Upsized Public Offering of Common Stock
December 8, 2020
Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for the Treatment of Danon Disease
December 7, 2020
Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American Society of Hematology Annual Meeting
December 6, 2020
Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual Meeting
December 5, 2020
Rocket Pharmaceuticals to Hold Webcast for Investors Highlighting Data Presented at the 62nd American Society of Hematology Annual Meeting
December 1, 2020
Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis
November 12, 2020
Rocket Pharmaceuticals to Present Data from its Fanconi Anemia, Leukocyte Adhesion Deficiency-I and Pyruvate Kinase Deficiency Programs at the 62nd American Society of Hematology Annual Meeting
November 3, 2020
Rocket Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Progress
November 3, 2020
Rocket Pharmaceuticals Presents Positive LAD-l Clinical Update and Comprehensive IMO Preclinical Review at the European Society for Immunodeficiencies 2020 Meeting
October 15, 2020
Rocket Pharmaceuticals Announces Two Presentations at the European Society for Immunodeficiencies 2020 Meeting
September 30, 2020
Rocket Pharmaceuticals Announces First Patient Treated in Higher Dose Cohort in Phase 1 Clinical Trial of RP-A501 for Danon Disease
September 1, 2020
Rocket Pharmaceuticals Receives FDA Fast Track Designation for RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis
August 26, 2020
Rocket Pharmaceuticals Expands Clinical Sites for its FA, Danon, LAD-I and IMO Trials, Adding to its Global Centers of Excellence
August 25, 2020
Rocket Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Progress
August 4, 2020
Rocket Pharmaceuticals Announces First Patient Treated in Phase 1 Trial of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency
July 12, 2020
Rocket Pharmaceuticals Announces FDA Clearance of IND for RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis
June 28, 2020
Rocket Pharmaceuticals Announces Private Exchange Transaction Regarding Its Outstanding Convertible Senior Notes due 2021
June 7, 2020
Rocket Pharmaceuticals Announces Participation at the Jefferies Virtual Healthcare Conference
May 25, 2020
Rocket Pharmaceuticals Presents Positive Updates on FA and LAD-I Gene Therapy Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy
May 11, 2020
Rocket Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Progress
May 5, 2020
Rocket Pharmaceuticals Announces Participation at the BofA Securities 2020 Health Care Conference
May 4, 2020
Rocket Pharmaceuticals Appoints Elisabeth Bjӧrk, M.D., Ph.D. to Board of Directors
April 21, 2020
Rocket Pharmaceuticals Provides Business Update in Light of COVID-19 Pandemic
April 1, 2020
Rocket Pharmaceuticals Announces Participation at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day
April 1, 2020
Rocket Pharmaceuticals Announces Science Translational Medicine Publication of its Program in Danon Disease
March 18, 2020
Rocket Pharmaceuticals Reports Full Year 2019 Financial Results and Operational Highlights
March 4, 2020
Rocket Pharmaceuticals Announces Publication of Manuscript Evaluating Mosaicism in Fanconi Anemia
February 23, 2020
Rocket Pharmaceuticals Announces Private Exchange Transactions Regarding Outstanding Convertible Senior Notes due 2021
February 10, 2020
Rocket Pharmaceuticals Supports Rare Disease Day® and Joins Global Movement to Raise Awareness
February 5, 2020
Rocket Pharmaceuticals Announces Participation at the 38th Annual J.P. Morgan Healthcare Conference
January 5, 2020
Decks in 2020
- Investor Day (December 2020)
Investor day · 41 slides · Dec 7, 2020
- Investor Presentation (December 2020)
Investor deck · 76 slides · December 2020